Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

The present invention relates to a process for preparing aminobenzoic acid or an aminobenzoic acid conversion product, comprising the steps of: (I) providing an aqueous solution of aminobenzoic acid using a fermentation process; (II) adsorbing aminobenzoic acid; (III) desorbing aminobenzoic acid at a pH in the range from −0.8 to 3.0, preferably −0.5 to 3.0, more preferably 0.1 to 3.0, very preferably 0.5 to 2.5, very exceptionally preferably 1.0 to 2.0; (IV) obtaining the aminobenzoic acid from the desorbate obtained in step (III); (V) optionally further converting the aminobenzoic acid obtained in step (IV) to an aminobenzoic acid conversion product.

The present invention relates to a process for preparing aminobenzoic acid or an aminobenzoic acid conversion product, comprising the steps of: (I) providing an aqueous solution of aminobenzoic acid using a fermentation process; (II) adsorbing aminobenzoic acid; (III) desorbing aminobenzoic acid at a pH in the range from −0.8 to 3.0, preferably −0.5 to 3.0, more preferably 0.1 to 3.0, very preferably 0.5 to 2.5, very exceptionally preferably 1.0 to 2.0; (IV) obtaining the aminobenzoic acid from the desorbate obtained in step (III); (V) optionally further converting the aminobenzoic acid obtained in step (IV) to an aminobenzoic acid conversion product.

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

A use of an anthranilic acid derivative as a matrix for a MALDI Mass spectrometry, comprising: preparing a matrix compound represented by the following formula:

##STR00001## wherein X is selected from hydrogen and a hydroxyl group, and Y is selected from hydrogen, a methyl group or an acetyl group, provided that when X is hydrogen, Y is hydrogen or an acetyl group, and when X is a hydroxyl group, Y is a methyl group; applying the matrix compound and an analyte onto a sample holder; and analyzing the analyte by the MALDI mass spectrometer.

A use of an anthranilic acid derivative as a matrix for a MALDI Mass spectrometry, comprising: preparing a matrix compound represented by the following formula:

##STR00001## wherein X is selected from hydrogen and a hydroxyl group, and Y is selected from hydrogen, a methyl group or an acetyl group, provided that when X is hydrogen, Y is hydrogen or an acetyl group, and when X is a hydroxyl group, Y is a methyl group; applying the matrix compound and an analyte onto a sample holder; and analyzing the analyte by the MALDI mass spectrometer.

The present invention relates to an improved process for the preparation of quinolone based compounds of general formula (I) using intermediate compound of general formula (XII). Invention also provides an improved process for the preparation of compound of formula (I-a) using intermediate compound of formula (XII-a) and some novel impurities generated during process. Compounds prepared using this process can be used to treat anemia.

Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of

##STR00001##

For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.